<VariationArchive RecordType="classified" VariationID="830441" VariationName="NC_000019.10:g.(?_11127998)_(11131359_?)del" VariationType="Deletion" Accession="VCV000830441" Version="1" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2022-11-05" DateCreated="2020-04-15" MostRecentSubmission="2020-04-15">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="821229" VariationID="830441">
      <GeneList>
        <Gene Symbol="LDLR" FullName="low density lipoprotein receptor" GeneID="3949" HGNC_ID="HGNC:6547" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>19p13.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="19" Accession="NC_000019.10" start="11089463" stop="11133820" display_start="11089463" display_stop="11133820" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" start="11200037" stop="11244505" display_start="11200037" display_stop="11244505" Strand="+" />
          </Location>
          <OMIM>606945</OMIM>
          <Haploinsufficiency last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2021-10-27" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=LDLR">No evidence available</Triplosensitivity>
          <Property>gene_acmg_incidental_2013</Property>
          <Property>gene_acmg_incidental_2016</Property>
          <Property>gene_acmg_incidental_2021</Property>
          <Property>gene_acmg_incidental_2022</Property>
        </Gene>
      </GeneList>
      <Name>NC_000019.10:g.(?_11127998)_(11131359_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>19p13.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="19" Accession="NC_000019.9" innerStart="11238674" innerStop="11242035" display_start="11238674" display_stop="11242035" variantLength="3362" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000019.9" sequenceAccession="NC_000019" sequenceVersion="9" change="g.(?_11238674)_(11242035_?)del" Assembly="GRCh37">
            <Expression>NC_000019.9:g.(?_11238674)_(11242035_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000019.10:g.(?_11127998)_(11131359_?)del AND Familial hypercholesterolemia" Accession="RCV001031075" Version="1">
        <ClassifiedConditionList TraitSetID="10706">
          <ClassifiedCondition DB="MedGen" ID="C0020445">Familial hypercholesterolemia</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2019-09-09" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2019-09-09" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2020-04-15" MostRecentSubmission="2020-04-15">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">1372927</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">1362925</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">16250003</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18718593</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">20828696</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">2760198</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29693183</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="10706" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="16649" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Familial hypercholesterolemia</ElementValue>
                <XRef ID="Familial+Hypercholesterolemia/2746" DB="Genetic Alliance" />
                <XRef ID="MONDO:0005439" DB="MONDO" />
                <XRef ID="398036000" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">FH</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Familial hypercholesterolemia (FH) is characterized by significantly elevated low-density lipoprotein cholesterol (LDL-C) that leads to atherosclerotic plaque deposition in the coronary arteries and proximal aorta at an early age and increases the risk of premature cardiovascular events such as angina and myocardial infarction; stroke occurs more rarely. Xanthomas (cholesterol deposits in tendons) may be visible in the Achilles tendons or tendons of the hands and worsen with age as a result of extremely high cholesterol levels. Xanthelasmas (yellowish, waxy deposits) can occur around the eyelids. Individuals with FH may develop corneal arcus (white, gray, or blue opaque ring in the corneal margin as a result of cholesterol deposition) at a younger age than those without FH. Individuals with a more severe phenotype, often as a result of biallelic variants, can present with very significant elevations in LDL-C (&gt;500 mg/dL), early-onset coronary artery disease (CAD; presenting as early as childhood in some), and calcific aortic valve disease.</Attribute>
                <XRef ID="NBK174884" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="practice guideline" Abbrev="NICE, 2019">
                <URL>https://www.nice.org.uk/guidance/CG71</URL>
                <CitationText>National Institute for Health and Clinical Excellence, Identification and management of familial hypercholesterolaemia, 2008 [Updated: 4 October 2019]</CitationText>
              </Citation>
              <Citation Type="general" Abbrev="PLoS Currents, 2011">
                <URL>http://knol.google.com/k/ren%C3%A9e-m-ned/cascade-screening-for-familial/70fnx9tmvdav/13?collectionId=28qm4w0q65e4w.50#</URL>
              </Citation>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">24404629</ID>
                <ID Source="BookShelf">NBK174884</ID>
              </Citation>
              <Citation Type="Position Statement" Abbrev="CSANZ, 2016">
                <URL>https://www.csanz.edu.au/wp-content/uploads/2017/07/Familial-Hypercholesterolaemia_ratified_-25-Nov-2016.pdf</URL>
                <CitationText>The Cardiac Society of Australia and New Zealand, Diagnosis and Management of Familial Hypercholesterolaemia â€“ Position Statement</CitationText>
              </Citation>
              <XRef ID="C0020445" DB="MedGen" />
              <XRef ID="MONDO:0005439" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS143890" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="2355635" SubmissionDate="2020-02-06" DateLastUpdated="2020-04-15" DateCreated="2020-04-15">
        <ClinVarSubmissionID localKey="6756139|MedGen:C0020445" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001194381" DateUpdated="2020-04-15" DateCreated="2020-04-15" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2019-09-09">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">1362925</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18718593</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">16250003</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">1372927</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">2760198</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29693183</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">20828696</ID>
          </Citation>
          <Comment>This variant is a gross deletion of the genomic region encompassing exons 16-18 of the LDLR gene. The 5' boundary is likely confined to intron 15. The 3' end of this event is unknown as it extends through the termination codon beyond the assayed region for this gene and may encompass additional genes. While this deletion is not anticipated to result in nonsense mediated decay, it is expected to create a truncated protein product or disrupt mRNA translation. A similar deletion of exons 16-18 has been observed to segregate with hypercholesterolemia in families (PMID: 1362925), and has been reported in several other affected individuals, particularly in Finnish populations (PMID: 1372927, 16250003, 18718593, 20828696, 29693183). This variant is also known as FH-Helsinki in the literature. A similar deletion of exons 16-18 has been reported to affect LDLR protein function in patient-derived fibroblasts (PMID: 2760198). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="LDLR" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000019.9:g.(?_11238674)_(11242035_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Familial hypercholesterolemia</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0020445" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB6933794</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="2355635" TraitType="Disease" MappingType="Name" MappingValue="Familial hypercholesterolemia" MappingRef="Preferred">
        <MedGen CUI="C0020445" Name="Familial hypercholesterolemia" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

